Profund Advisors LLC trimmed its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,026 shares of the biopharmaceutical company’s stock after selling 3,506 shares during the quarter. Profund Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $13,168,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of REGN. Nippon Life Global Investors Americas Inc. grew its stake in Regeneron Pharmaceuticals by 26.3% during the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 36,540 shares of the biopharmaceutical company’s stock worth $13,737,000 after buying an additional 7,610 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Regeneron Pharmaceuticals by 516.8% in the 4th quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock valued at $217,892,000 after purchasing an additional 485,600 shares during the last quarter. Senzar Asset Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 46.8% in the 4th quarter. Senzar Asset Management LLC now owns 113,500 shares of the biopharmaceutical company’s stock valued at $42,671,000 after buying an additional 36,200 shares during the period. Sectoral Asset Management Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 19.4% in the 4th quarter. Sectoral Asset Management Inc now owns 39,316 shares of the biopharmaceutical company’s stock valued at $14,781,000 after buying an additional 6,399 shares during the period. Finally, MML Investors Services LLC raised its holdings in Regeneron Pharmaceuticals by 19.6% during the fourth quarter. MML Investors Services LLC now owns 4,731 shares of the biopharmaceutical company’s stock worth $1,779,000 after purchasing an additional 774 shares during the last quarter. Institutional investors own 66.40% of the company’s stock.
A number of research firms have recently weighed in on REGN. Argus cut their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a report on Thursday, December 28th. BTIG Research reissued a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $522.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Credit Suisse Group set a $440.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, Guggenheim set a $530.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $449.49.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded up $3.67 on Wednesday, reaching $341.42. 577,805 shares of the company traded hands, compared to its average volume of 999,121. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 1-year low of $313.53 and a 1-year high of $543.55. The company has a market cap of $37,106.66, a PE ratio of 33.08, a P/E/G ratio of 1.08 and a beta of 1.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.04 EPS. equities research analysts predict that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $340.00, for a total transaction of $680,000.00. Following the transaction, the director now owns 14,000 shares in the company, valued at approximately $4,760,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/14/profund-advisors-llc-sells-3506-shares-of-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.